SFX by Ex Libris Inc.

Title:	Influence, integrity, and the FDA: An ethical framework
Source:	Science [0036-8075] Hey, S P yr:2017

Basic

Sorry, no full text available...

Please use the document delivery service (see below)

Holding information

Holdings in library search engine ALBERT

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	"Kennametal one of the world's most ethical companies." Metal powder report 72.4: 226-226.
description	2.	Rai, A. "Use patents, carve-outs, and incentives--a new battle in the drug-patent wars." The New England journal of medicine 367.6 (2012): 491-493.
description	3.	Suh, G. "High medicine prices and poor affordability." Current opinion in psychiatry 24.4 (2011): 341-5.
description	4.	"The world's most ethical companies.(Hindsight)." Risk management 57.4 (2010): 47-.
description	5.	"Kennametal among world's most ethical companies." Metal Powder Report 69.3 (2014): 8-8.
description	6.	"TIMKEN SELECTED AS ONE OF WORLD'S MOST ETHICAL COMPANIES." Tribology & lubrication technology. 72.5: 74-75.
description	7.	Somaya, D. "Patent Strategy and Management: An Integrative Review and Research Agenda." Journal of management 38.4 (2012): 1084-1114.
description	8.	Turner, R S. "Of Milk and Mandarins: rBST, Mandated Science and the Canadian Regulatory Style." Journal of Canadian studies 36.3 (2001): 107-130.
description	9.	Goldman, D. "Patient cost-sharing and healthcare spending growth." The journal of economic perspectives 25.2 (2011): 47-68.
description	10.	Carrier, Michael A. Innovation for the 21st century harnessing the power of intellectual property and antitrust law. Oxford University Press,, 2009.
description	11.	Kotwani, A. "Where are we now: assessing the price, availability and affordability of essential medicines in Delhi as India plans free medicine for all." BMC health services research 13.1 (2013): 285-285.
description	12.	Buell, John M. "Innovation in healthcare." Healthcare executive 29.3 (2014): 32-4.
description	13.	Candelin Palmqvist, H. "Intellectual property rights in innovation management research : A review." Technovation ISSU.PAGE (2012): 502-512.
description	14.	Kirby, T. "Europe to boost development of new antimicrobial drugs." Lancet 379.9833 (2012): 2229-2230.
description	15.	Choi, Tae H. "Do ethical companies have lower implied cost of equity capital? Evidence from the Korean stock market." Asian Business & Management 11.2 (2012): 219-246.
description	16.	Meiners, C. "Modeling HIV/AIDS Drug Price Determinants in Brazil: Is Generic Competition a Myth?" PLoS ONE 6.8 (2011): 8-8.
description	17.	Somaya, D. "Innovation in Multi-Invention Contexts: MAPPING SOLUTIONS TO TECHNOLOGICAL AND INTELLECTUAL PROPERTY COMPLEXITY." California management review 53.4 (2011): 47-79.
description	18.	Wilfred, D. "Patent strategizing." Journal of intellectual capital 12.2 (2011): 168-178.
description	19.	Bratt, John H. "Costs of HIV/AIDS outpatient services delivered through Zambian public health facilities." TM & IH. Tropical medicine & international health 16.1 (2011): 110-118.
description	20.	Cook, Arthur G. "Forecasting for the Pharmaceutical Industry : Models for New Product and In-Market Forecasting and How to Use Them." Forecasting for the pharmaceutical industry : models for new product and in-market forecasting and how to use them. 2006.